Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- New Group Led by MRI to Issue Clinical Trial Policy Proposals by September 2024
November 22, 2023
- Israel-Palestine Conflict to Have Limited Impact on Japan Pharma Sector for Now: JPMA
November 17, 2023
- JPMA Gearing Up for Drug Pricing Reform Debate towards December: Exec
November 17, 2023
- Policy Veterans’ Group Renews Call for Company-Proposed Pricing, Floats Support System for Biosimilars
November 15, 2023
- PhRMA Chief Presses Japan to Cut LLP Spending, Shift Funds towards Innovation
November 15, 2023
- PhRMA Chair Urges Japan to Maintain On-Patent Drug Prices, Improve Initial Pricing
November 10, 2023
- Diabetes Groups Urge Govt to Build Stable Supply System for GLP-1s, Other Meds
November 8, 2023
- Chuikyo Rep Interview 4 - JMA Rep Says Any Reform Must Ensure Access to Appropriate Healthcare
November 6, 2023
- GHIT Fund, MPP to Bolster Ties to Enhance Drug Access
October 31, 2023
- 70% of Younger Wholesaler Staffers Ponder Quitting Jobs amid Supply Crunch: Poll
October 30, 2023
- Shipments Curbed or Suspended for 22.9% of Products in September: FPMAJ
October 27, 2023
- Japan Needs New Rule to Price Drugs on Par with US, Europe: JPMA Director
October 27, 2023
- JMA to Seek Wage Hike of “at Least 3%” in 2024 Revision: President
October 27, 2023
- Chuikyo Rep Interview 3-2 - Rengo Wants Substantive Discussions on Pricing System, Off-Year Revisions over Next Few Years
October 26, 2023
- Off-Label Use of GLP-1 Goes against Medical Ethics: JMA Executive
October 26, 2023
- Chuikyo Rep Interview 3-1 - Rengo Seeks Patient-Centric Debate, Sees Exhausted Wholesalers as Big Issue
October 25, 2023
- Neurology Society, SMA Group Urge Nationwide Newborn Test at Public Expense
October 20, 2023
- No Info Received from Member Firms on Impact of Middle East Crisis: JPMA
October 20, 2023
- JGA Vows Cooperation after Generic Panel’s Interim Report
October 20, 2023
- JPMA Renews Call for Abolishing PMP Company Criteria
October 20, 2023
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…